Xikui Chen
FDA investigator
Appears on 3 documents from 2010 to 2023, mostly at sites in Texas. Most often cites analytical methods for an in vivo bioavailability or bioequivalence study (21 CFR 320.29).
- 3
- Documents on file
- 3.5
- Observations per 483
- 2010
- First seen
- 2023
- Most recent
What they cite most
From 7 observations- 21 CFR 320.29Analytical methods for an in vivo bioavailability or bioequivalence study1
Activity by year
2010: 1, 2011: 1, 2023: 1
Where
Texas 2 · New York 1
Often inspects with
Is Xikui Chen coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
3 documents, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2023-04-21 | 483 ScieGen Pharmaceuticals, INC.Apr 21, 2023 · Hauppauge, New York | Hauppauge, New York | 1 | |
| 2011-07-26 | Warning letter Cetero ResearchJul 26, 2011 · Houston, Texas | Houston, Texas | — | |
| 2010-12-10 | 483 Cetero ResearchDec 10, 2010 · Houston, Texas | Houston, Texas | 6 |
About this profile
What does Xikui Chen inspect?
Xikui Chen appears on 3 documents on file covering 2 sites, mostly in Texas.
What do they cite most often?
21 CFR 320.29 (analytical methods for an in vivo bioavailability or bioequivalence study).
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Xikui Chen is dated Apr 21, 2023.